FDA approves apalutamide for treatment of mCSPC here in US

Yesterday (September 17, 2019), the US Food and Drug Administration approved apalutamide (Erleada) for treatment of men with metastatic castration-sensitive prostate cancer (mCSPC) … READ MORE …

SABR to oligometastases slows progression via immune response

Stereotactic ablative body radiation (SABR, or sometimes, SBRT) significantly slowed metastatic progression in men with three or fewer metastases (oligometastatic disease). … READ MORE …

Complementary and alternative medicines in management of prostate cancer

A newly published paper in the Journal of Urology has reported on the use of complementary and alternative medicines (CAMs) among a cohort of nearly 8,000 American patients with a diagnosis of prostate cancer between 1996 and 2016. … READ MORE …

PCaI extends low-cost room rate for conference in Virginia Beach

Prostate Cancer International (PCaI) has been able extend the hotel discount deadline to Monday, Oct 7th for its FREE patient conference in Virginia Beach on November 2. … READ MORE …

Lifestyle, diet, exercise, and cancer

The Prostate Cancer Foundation (PCF) has recently issued a new “booklet” (it’s about 90 pages in length) entitled, The Science of Living Well, Beyond Cancer. … READ MORE …

High-dose vitamin D: negative results from a randomized clinical trial

Data from a recently published, Canadian, clinical trial of high-dose vitamin D as a method to strengthen bones in healthy adults who do not have osteoporesis have had significant and unexpectedly negative results. … READ MORE …

The APCCC in Basel, Switzerland: Day 3

So today, the third day of the meeting, was “voting day” on a total of 123 questions carefully crafted by the organizers prior to the meeting. The questions had all gone through three cycles of review and revision prior to the meeting. … READ MORE …